He is graduated in Medicine from the Universidad de Barcelona in 1992, where he also obtained his Ph.D. degree specialising in molecular genetics of endometrial carcinoma, in 1996. He was an Invited Researcher at the School of Biological and Medical Sciences at the University of St. Andrews, (Scotland, UK) during which time his research interests focused on the molecular genetics of inherited breast cancer. From 1997 to 2001, Esteller was a Postdoctoral Fellow and a Research Associate at the Johns Hopkins University and School of Medicine, (Baltimore, USA) where he studied DNA methylation and human cancer. His work was decisive in establishing promoter hypermethylation of tumour suppressor genes as a common hallmark of all human tumours. From 2001 to 2008 Manel Esteller was the Leader of the CNIO Cancer Epigenetics Laboratory in Madrid, where his principal area of research were the alterations in DNA methylation, histone modifications and chromatin in human cancer. Since October 2008, Dr Esteller is the Director of the Cancer Epigenetics and Biology Program (PEBC) of the Bellvitge Institute for Biomedical Research (IDIBELL) in Barcelona, Chairman of Genetics in the School of Medicine of the University of Barcelona, and an ICREA Research Professor. Author of more than five-hundred manuscripts in the biomedical field, many of them as Highly Cited articles, he also serves as associated editor for several journals and he has been the recipient, among others, of the Carcinogenesis Award (2005), Swiss Bridge Award (2006), DEbiopharm-EPFL Award (2009), Dr. Josef Steiner Cancer Research Award (2009), Premio de Investigacion Biomedica Fundacion Lilly (2009), World Health Summit Award (2010), European Research Council Advanced Grant (2011), Severo Ochoa Prize for Biomedical Research by Ferrer Foundation (2013), Research Award in Life Sciences Royal Academy of Natural and Physical Sciences (2013), National Award in Oncology (2014), National Research Prize of the Catalan Government (2015), Gold Medal of the Parliament of Catalonia (2016) and the International Award of Catalonia (2016). His current research is devoted to the establishment of the epigenome maps of normal and transformed cells, the study of the interactions between epigenetic modifications and non-coding RNAs, and the development of new epigenetic drugs for cancer therapy.